- Home
- TYGO vs CNTX Comparison
TYGO vs CNTX Comparison
Compare TYGO & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- CNTX
- Stock Information
- Founded
- TYGO 2007
- CNTX 2015
- Country
- TYGO United States
- CNTX United States
- Employees
- TYGO N/A
- CNTX N/A
- Industry
- TYGO Semiconductors
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- CNTX Health Care
- Exchange
- TYGO Nasdaq
- CNTX Nasdaq
- Market Cap
- TYGO 82.5M
- CNTX 78.0M
- IPO Year
- TYGO N/A
- CNTX 2021
- Fundamental
- Price
- TYGO $1.25
- CNTX $0.84
- Analyst Decision
- TYGO Strong Buy
- CNTX Strong Buy
- Analyst Count
- TYGO 2
- CNTX 5
- Target Price
- TYGO $3.75
- CNTX $5.50
- AVG Volume (30 Days)
- TYGO 55.1K
- CNTX 197.0K
- Earning Date
- TYGO 07-29-2025
- CNTX 08-06-2025
- Dividend Yield
- TYGO N/A
- CNTX N/A
- EPS Growth
- TYGO N/A
- CNTX N/A
- EPS
- TYGO N/A
- CNTX N/A
- Revenue
- TYGO $63,051,000.00
- CNTX N/A
- Revenue This Year
- TYGO $69.44
- CNTX N/A
- Revenue Next Year
- TYGO $21.75
- CNTX N/A
- P/E Ratio
- TYGO N/A
- CNTX N/A
- Revenue Growth
- TYGO N/A
- CNTX N/A
- 52 Week Low
- TYGO $0.58
- CNTX $0.49
- 52 Week High
- TYGO $1.80
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- TYGO 48.66
- CNTX 64.84
- Support Level
- TYGO $1.27
- CNTX $0.82
- Resistance Level
- TYGO $1.36
- CNTX $0.87
- Average True Range (ATR)
- TYGO 0.10
- CNTX 0.07
- MACD
- TYGO -0.01
- CNTX 0.01
- Stochastic Oscillator
- TYGO 22.22
- CNTX 58.27
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.